A clinical pharmacologist is analyzing the steady-state trough concentrations of a newly approved monoclonal antibody targeted for severe refractory eosinophilic asthma. In a post-marketing surveillance cohort of adult patients, the serum trough concentrations follow a normal, symmetric bell-shaped distribution.
The variance of the steady-state trough concentrations in this population is calculated to be . Furthermore, statistical analysis reveals that the percentile for the trough concentration is .
The clinical trial protocol dictates that any patient with a trough concentration falling at or below the percentile is at extremely high risk for subtherapeutic exposure and should undergo immediate dose escalation.
Below what trough concentration (in ) will a patient qualify for this dose escalation?
Cevap: 8 mcg/mL